Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Elanco Animal Health has received a consensus rating of "Moderate Buy" from nine brokerages, with an average 12-month price target of $17.33.
• The company reported earnings of $0.26 per share for the last quarter, beating expectations, and indicated a revenue increase of 4.8% compared to the previous year.
• Institutional investors own 97.48% of Elanco's stock, highlighting strong institutional confidence in the company.

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine brokerages that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $17.3333.

A number of research analysts recently issued reports on the company. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Piper Sandler increased their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, August 11th. Wall Street Zen upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Leerink Partnrs upgraded Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 17th. Finally, Stifel Nicolaus boosted their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd.

Elanco Animal Health Trading Up 0.1%

Shares of ELAN stock opened at $18.65 on Wednesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. The company has a market cap of $9.27 billion, a price-to-earnings ratio of 21.69, a PEG ratio of 3.46 and a beta of 1.62. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $19.08. The firm has a fifty day moving average price of $16.53 and a 200-day moving average price of $13.30.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.06. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.Elanco Animal Health's quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Allworth Financial LP boosted its holdings in shares of Elanco Animal Health by 791.7% during the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock valued at $25,000 after purchasing an additional 2,090 shares during the last quarter. NBC Securities Inc. purchased a new stake in shares of Elanco Animal Health in the first quarter worth about $40,000. Parallel Advisors LLC boosted its stake in Elanco Animal Health by 92.2% during the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock valued at $41,000 after buying an additional 1,852 shares during the last quarter. Versant Capital Management Inc grew its holdings in Elanco Animal Health by 65.9% during the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after buying an additional 1,740 shares in the last quarter. Finally, First Horizon Advisors Inc. increased its stake in Elanco Animal Health by 184.3% in the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company's stock worth $53,000 after acquiring an additional 2,414 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.